<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01130779</url>
  </required_header>
  <id_info>
    <org_study_id>2009-07-078</org_study_id>
    <nct_id>NCT01130779</nct_id>
  </id_info>
  <brief_title>The Continuation of Erlotinib</brief_title>
  <official_title>The Continuation of Erlotinib Treatment in Non-small Cell Lung Cancer Patients Whose Brain Lesion is the Only Site of Progression : Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <brief_summary>
    <textblock>
      Newly developed or progressive brain metastasis during erlotinib treatment is considered&#xD;
      progressive disease requiring change of treatment regimens despite no progression in&#xD;
      extracranial lesions. Given that there is a dissociation in terms of response to erlotinib&#xD;
      between brain and extracranial sites, we intend to conduct this pilot study to determine&#xD;
      whether the continuation of erlotinib treatment can prolong the progression free interval of&#xD;
      extracranial lesions as long as cranial lesion is controlled separately by conventional&#xD;
      treatment modalities such as surgical resection, stereotactic radiosurgery, and whole brain&#xD;
      radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>August 2009</start_date>
  <primary_completion_date type="Anticipated">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to treatment failure</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity profiles</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>tarceva</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>continuation of tarceva</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib (TARCEVAÂ®)</intervention_name>
    <description>Erlotinib 150mg/day, everyday</description>
    <arm_group_label>tarceva</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically proven non small cell lung cancer&#xD;
&#xD;
          2. New developed or progression of brain lesions among patients with good control of&#xD;
             extracranial lesions to erlotinib&#xD;
&#xD;
          3. patients who are receiving erlotinib as salvage therapy&#xD;
&#xD;
          4. At least one unidimensionally measurable lesion with a diameter &gt; 10mm using brain MRI&#xD;
&#xD;
          5. at least on unidimensionally measurable or evaluable lesion&#xD;
&#xD;
          6. male or female patients aged &gt;18 years&#xD;
&#xD;
          7. ECOG performance status 0-2&#xD;
&#xD;
          8. Adequate hematologic function&#xD;
&#xD;
          9. adequate renal function&#xD;
&#xD;
         10. adequate hepatic function&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. leptomeningeal metastases&#xD;
&#xD;
          2. acute severe infection requiring antibiotic therapy&#xD;
&#xD;
          3. significant cardiovascular disease&#xD;
&#xD;
          4. uncontrolled DM&#xD;
&#xD;
          5. severe ophthalmologic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myungju Ahn, Ph.D., M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>May 25, 2010</study_first_submitted>
  <study_first_submitted_qc>May 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2010</study_first_posted>
  <last_update_submitted>May 25, 2010</last_update_submitted>
  <last_update_submitted_qc>May 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Myungju Ahn Ph.D., M.D.</name_title>
    <organization>Samsung Medical Center</organization>
  </responsible_party>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>brain metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

